NASDAQ$GYRE
Gyre Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported second quarter 2024 financial results and provided a business update.
Gyre Therapeutics reported revenues of $25.2 million and a net income of $4.5 million for the second quarter ended June 30, 2024. The company received NMPA approval for avatrombopag maleate tablets and IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension.
- Received NMPA approval of avatrombopag maleate tablets for CLD-associated thrombocytopenia.
- Received IND approval from NMPA to evaluate F230 for pulmonary arterial hypertension.
- U.S. IND submission for F351 in MASH-associated liver fibrosis expected in late 2024.
- Phase 3 trial data readout from CHB-associated liver fibrosis in the PRC expected by early 2025.
Headline financials
Revenue & EPS history
Gyre Therapeutics · Revenue · Quarterly
$25.2M
Revenue by segment
Gyre Therapeutics · $2.3M total across 1 segment · Q3 2021
- License & Collaboration$2.3M—100.0%
Forward guidance
Gyre anticipates that its cash resources as of June 30, 2024 will enable it to fund operations through at least 12 months following the issuance of the condensed consolidated financial statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+8.5%
Avg return
30 days after
49%
23 / 47 earnings
Positive
+11.6%
Q3 2018
Best reaction
-43.2%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.8% | +2.8% | -11.2% | |
| Q4 2025 | +2.0% | -10.2% | -5.4% | |
| Q3 2025 | -1.6% | +13.6% | +8.7% | |
| Q1 2025 | +0.5% | +9.6% | -11.3% | |
| Q3 2024 | -13.6% | -21.2% | -39.8% | |
| Q2 2024 | -6.5% | +2.1% | +28.7% | |
| Q1 2024 | -5.5% | +0.5% | -29.3% | |
| Q4 2023 | +8.3% | +8.0% | +0.9% | |
| Q3 2023 | +0.0% | -15.3% | +144.2% | |
| Q2 2023 | +8.8% | +58.8% | +50.0% | |
| Q1 2023 | +5.0% | +5.0% | +5.0% | |
| Q4 2022 | +5.0% | +5.0% | +5.0% | |
| Q3 2022 | -1.8% | +0.0% | -12.5% | |
| Q2 2022 | -1.6% | +3.6% | +2.1% | |
| Q1 2022 | -24.5% | -26.5% | +173.5% | |
| Q4 2021 | +0.0% | -3.0% | -27.3% | |
| Q3 2021 | -43.2% | -51.0% | -62.9% | |
| Q2 2021 | +7.4% | +3.7% | +10.3% | |
| Q1 2021 | -2.4% | -5.4% | -9.5% | |
| Q3 2020 | +4.5% | +7.4% | +11.3% | |
| Q2 2020 | -0.6% | -2.0% | -13.5% | |
| Q1 2020 | +7.2% | -2.7% | +21.9% | |
| Q3 2019 | -3.1% | -6.1% | -8.7% | |
| Q2 2019 | +6.7% | -3.2% | -22.1% | |
| Q1 2019 | -5.3% | +2.7% | -9.2% | |
| Q3 2018 | +11.6% | +24.7% | +20.0% | |
| Q2 2018 | +6.6% | +6.6% | +11.9% | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +1.2% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | -5.4% | — | — | |
| Q2 2013 | -3.6% | — | — | |
| Q1 2013 | +0.5% | — | — | |
| Q4 2012 | -0.5% | — | — | |
| Q3 2012 | +0.7% | — | — | |
| Q2 2012 | -0.9% | — | — | |
| Q1 2011 | -2.7% | — | — | |
| Q1 2012 | +0.4% | — | — | |
| Q4 2011 | +0.1% | — | — | |
| Q4 2009 | +0.1% | — | — | |
| Q3 2010 | +3.9% | — | — | |
| Q3 2011 | +3.9% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q4 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro